Nuvectis Pharma(US:NVCT)2026-02-11 13:10Financial Performance - Nuvectis Pharma reported a net loss of $26.4 million for the year ended December 31, 2025, an increase of 39% from a net loss of $19.0 million in 2024[4] - The basic and diluted net loss per common share was $1.32 for 2025, compared to $1.11 for 2024[13] - General and administrative expenses were $9.4 million for 2025, a 36% increase from $6.9 million in 2024[5] - Research and development expenses rose to $18.2 million in 2025, up 41% from $12.9 million in 2024[4] - The total shareholders' equity increased to $18.4 million in 2025, up from $9.7 million in 2024, reflecting a significant growth in equity[11] Cash Position - Cash and cash equivalents increased to $31.6 million as of December 31, 2025, compared to $18.5 million at the end of 2024, reflecting a $13.1 million increase[3] - Nuvectis anticipates that its current cash position will support operations through multiple NXP900 Phase 1b milestones and into the second half of 2027[2] Development Programs - The company is focused on developing NXP900, an oral small molecule inhibitor targeting SRC Family of Kinases, with ongoing clinical trials[6] - Nuvectis is preparing to commence a combination study of NXP900 with lorlatinib in ALK-positive non-small cell lung cancer patients[2] - The company expects multiple potential data readouts for the NXP900 development program in 2026, indicating a focus on operational execution and financial responsibility[2]